{'52WeekChange': -0.09674263,
 'SandP52WeekChange': 0.0644362,
 'address1': '121 Seaport Boulevard',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 101.65,
 'askSize': 800,
 'averageDailyVolume10Day': 1593487,
 'averageVolume': 2082709,
 'averageVolume10days': 1593487,
 'beta': 1.467787,
 'beta3Year': None,
 'bid': 101.25,
 'bidSize': 900,
 'bookValue': 53.133,
 'category': None,
 'circulatingSupply': None,
 'city': 'Boston',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 104.455,
 'dayLow': 100.83,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': -0.052,
 'enterpriseToEbitda': 8.387,
 'enterpriseToRevenue': 4.324,
 'enterpriseValue': 22896275456,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '203 271 8198',
 'fiftyDayAverage': 111.613716,
 'fiftyTwoWeekHigh': 125.52,
 'fiftyTwoWeekLow': 72.67,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 220187031,
 'forwardEps': 11.7,
 'forwardPE': 8.674359,
 'fromCurrency': None,
 'fullTimeEmployees': 3082,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.0029699998,
 'heldPercentInstitutions': 0.95391,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1306108800,
 'lastSplitFactor': '2:1',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/alexion.com',
 'longBusinessSummary': 'Alexion Pharmaceuticals, Inc. develops and '
                        'commercializes various therapeutic products. The '
                        'company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), '
                        'a monoclonal antibody for the treatment of paroxysmal '
                        'nocturnal hemoglobinuria (PNH), a genetic blood '
                        'disorder; and Soliris (eculizumab), a monoclonal '
                        'antibody for the treatment of PNH, atypical hemolytic '
                        'uremic syndrome (aHUS), and generalized myasthenia '
                        'gravis. It also provides Strensiq (asfotase alfa), a '
                        'targeted enzyme replacement therapy for patients with '
                        'hypophosphatasia; and Kanuma (sebelipase alfa) for '
                        'the treatment of patients with lysosomal acid lipase '
                        'deficiency. In addition, the company conducts Phase '
                        'III clinical trials for ALXN 1210 (IV) for the '
                        'treatment of PNH and aHUS; ALXN1210 (Subcutaneous), '
                        'which is in Phase I for PNH and aHUS; and Soliris '
                        '(eculizumab) for the treatment of myasthenia gravis '
                        'and neuromyelitis optica spectrum disorder. Further, '
                        'it develops ALXN1840 that is in Phase III clinical '
                        'trials for the treatment of Wilson disease; and '
                        'ALXN1830, which is in Phase II clinical trials for '
                        'the treatment of warm autoimmune hemolytic anemia. '
                        'The company serves distributors, pharmacies, '
                        'hospitals, hospital buying groups, and other '
                        'healthcare providers in the United States and '
                        'internationally. Alexion Pharmaceuticals, Inc. has '
                        'collaboration and license agreement with Halozyme '
                        'Therapeutics, Inc. to use drug-delivery technology in '
                        'the development of subcutaneous formulations for its '
                        'portfolio of products; collaboration with Dicerna '
                        'Pharmaceuticals, Inc. to discover and develop RNAi '
                        'therapies for complement-mediated diseases, as well '
                        'as with Zealand Pharma A/S; strategic agreement with '
                        'Caelum Biosciences, Inc. to advance the development '
                        'of CAEL-101 for light chain amyloidosis; agreement '
                        'with Stealth BioTherapeutics Corp. to co-develop and '
                        'commercialize therapy for mitochondrial diseases; and '
                        'a partnership with Affibody AB. The company was '
                        'founded in 1992 and is headquartered in Boston, '
                        'Massachusetts.',
 'longName': 'Alexion Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 22411732992,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_347983',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': 2374000128,
 'nextFiscalYearEnd': 1640908800,
 'open': 104.4,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 0.77,
 'phone': '475 230 2596',
 'previousClose': 104.79,
 'priceHint': 2,
 'priceToBook': 1.9101124,
 'priceToSalesTrailing12Months': 4.2322226,
 'profitMargins': 0.44831002,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 104.455,
 'regularMarketDayLow': 100.83,
 'regularMarketOpen': 104.4,
 'regularMarketPreviousClose': 104.79,
 'regularMarketPrice': 104.4,
 'regularMarketVolume': 2437430,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 220827008,
 'sharesPercentSharesOut': 0.0216,
 'sharesShort': 4764023,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 4501640,
 'shortName': 'Alexion Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.0225,
 'shortRatio': 2.27,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'ALXN',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': 10.592,
 'trailingPE': 9.581759,
 'twoHundredDayAverage': 102.89726,
 'volume': 2437430,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.alexion.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02210'}